News - Trius Therapeutics, Cubist Pharmaceuticals

Filter

Popular Filters

Unanimous FDA advisory panel backing for Cubist’s Sivextro

Unanimous FDA advisory panel backing for Cubist’s Sivextro

02-04-2014

The US Food and Drug Administration’s Anti-Infective Drugs Advisory Committee on Monday voted unanimously…

Antibiotics and Infectious diseasesCubist PharmaceuticalsNorth AmericaPharmaceuticalRegulationSivextrotedizolidUSA

Cubist’s tedizolid NDA accepted for priority review in USA

Cubist’s tedizolid NDA accepted for priority review in USA

31-12-2013

The US Food and Drug Administration has accepted Cubist Pharmaceuticals’ New Drug Application for its…

Antibiotics and Infectious diseasesBayerCubist PharmaceuticalsNorth AmericaPharmaceuticalRegulationtedizolidTrius TherapeuticsUSA

New Ph III data support early 2014 filing for Cubist’s ceftolozane/tazobactam

New Ph III data support early 2014 filing for Cubist’s ceftolozane/tazobactam

17-12-2013

US drugmaker Cubist Pharmaceuticals saw its shares jump 8.3% to $68 in premarket trading yesterday, when…

Antibiotics and Infectious diseasesceftolozoneCubist PharmaceuticalsEuropeNorth AmericaPharmaceuticalRegulationResearchtazobactam

Positive top-line Ph III results with ceftolozane/tazobactam in cUTI

25-11-2013

US biopharma company Cubist Pharmaceuticals has revealed positive top-line results from its pivotal Phase…

Antibiotics and Infectious diseasesceftolozaneCubist PharmaceuticalsGenito-urinaryPharmaceuticalResearchtazobactam

Opioid-induced constipation market expected to see rapid growth by 2017

Opioid-induced constipation market expected to see rapid growth by 2017

13-10-2013

The global market for opioid-induced constipation will increase significantly from $144.42 million in…

AstraZenecabevenopranCubist PharmaceuticalsEuropeGastro-intestinalsMarkets & MarketingnaloxegolNorth AmericaPharmaceuticalRelistorSalix Pharmaceuticals

July a strong month for life sciences IPOs and M&A

05-08-2013

The life sciences initial public offering (IPO) market continued to heat up in July as six life sciences…

BiotechnologyCubist PharmaceuticalsFinancialMergers & AcquisitionsPerrigoPharmaceuticalRoche

Cubist Pharma signs two acquisition deals in one day

31-07-2013

In what must have been a busy day for US drugmaker Cubist Pharmaceuticals (Nasdaq: CBST) announced not…

Antibiotics and Infectious diseasesCubist PharmaceuticalsDificidMergers & AcquisitionsOptimer PharmaceuticalsPharmaceuticaltedizolidTrius Therapeutics

Heptares gets first research milestone from Cubist

22-07-2013

UK GPCR drug discovery and development company Heptares Therapeutics says it has achieved the first research…

Cubist PharmaceuticalsFinancialHeptares TherapeuticsPharmaceuticalResearch

Clinigen and Theravance deal on Vibativ; Cubist expands rights to ceftolozane

12-03-2013

UK-based Clinigen Group (LSE: CLIN ) and Theravance (Nasdaq: THRX) of the USA have entered into an exclusive…

Antibiotics and Infectious diseasesAstellas PharmaceftolozaneClinigen GroupCubist PharmaceuticalsEuropeGlobalLicensingPharmaceuticalTheravanceVibativ

Cubist gains exclusive option to acquire Adynxx

26-02-2013

US drugmaker Cubist Pharmaceuticals (Nasdaq: CBST) has entered into an option agreement with privately-held,…

AdynxxAYX1Cubist PharmaceuticalsMergers & AcquisitionsPharmaceutical

Cubist partners with Heptares on new medicines targeting GPCRs; provides 2012 business update

08-01-2013

UK-based Heptares Therapeutics, the leading GPCR drug discovery and development company, has signed an…

ceftolozaneCubist PharmaceuticalsFinancialGenito-urinaryHeptares TherapeuticsLicensingPharmaceuticalResearchtazobactam

Cubist unveils five-year strategic goals; enters antibiotics collaboration

12-06-2012

USA-based Cubist Pharmaceuticals (Nasdaq: CBST) has announced its five-year strategic aspirations - Building…

Antibiotics and Infectious diseasesCubicinCubist PharmaceuticalsEnteregFinancialFundacion MEDINAPharmaceuticalResearch

Hospira challenges Cubist patents on Cubicin

10-02-2012

US drugmaker Cubist Pharmaceuticals (Nasdaq: CBST) says that it has received a Paragraph IV Notice Letter…

Antibiotics and Infectious diseasesCubicinCubist PharmaceuticalsGenericsHospiraNorth AmericaPatentsPharmaceuticalResearch

Ferring Pharma acquires Cytokine PharmaSciences; Cubist buys Adolor

25-10-2011

Switzerland-based Ferring Pharmaceuticals says that it has completed the purchase of USA-based Cytokine…

AdolorCubist PharmaceuticalsCytokine PharmaSciencesEnteregFerring PharmaceuticalsGastro-intestinalsMergers & AcquisitionsPharmaceuticalReproductive

Optimer/Cubist’s Dificid poised to challenge Vancocin usage in C. difficile treatment; report

14-09-2011

Less than half of surveyed infectious disease (ID) specialists and only 6% of surveyed internists demonstrated…

Antibiotics and Infectious diseasesCubist PharmaceuticalsDificidMarkets & MarketingNorth AmericaOptimer PharmaceuticalsPharmaceuticalVancocin

US FDA approves Optimer’s Dificid for C. difficile infection

31-05-2011

Following a positive advisory panel recommendation last month, the US Food and Drug Administration has…

Antibiotics and Infectious diseasesCubist PharmaceuticalsDificidNorth AmericaOptimer PharmaceuticalsPharmaceuticalRegulation

Vancomycin continues to dominate MRSA treatment with up to 76% of US specialists using the drug; Study

25-05-2011

According to surveyed infectious disease specialists and internists in the USA, as well as hospital patient-level…

Antibiotics and Infectious diseasesCubicinCubist PharmaceuticalsMarkets & MarketingNorth AmericaPfizerPharmaceuticalVancomycinZyvox

Company Spotlight

Fibrotech

Fibrotech

Back to top